Table 1 TRIPOD adherence reporting items
Reporting Items | Study design | If applicable to studies | Reporting items for TRIPOD adherence | |
|---|---|---|---|---|
Development only | Development and validation | |||
 1. Title | D, V | ✓ | ✓ | |
 2. Abstract | D, V | ✓ | ✓ | |
Introduction | ||||
 3. Background and objectives | ||||
  a. Context and rationale | D, V | ✓ | ✓ | |
  b. Objectives | D, V | ✓ | ✓ | |
Methods | ||||
 4. Source of data | ||||
  a. Source of data | D, V | ✓ | ✓ | |
  b. Key dates | D, V | ✓ | ✓ | |
 5. Participants | ||||
  a. Study setting | D, V | ✓ | ✓ | |
  b. Eligibility criteria | D, V | ✓ | ✓ | |
  c. Details of treatment | D, V | ✓ | ✓ | ✓ |
 6. Outcome | ||||
  a. Outcome definition | D, V | ✓ | ✓ | |
  b. Blinding of outcome assessment | D,V | ✓ | ✓ | |
 7. Predictors | ||||
  a. Predictors definition | D, V | ✓ | ✓ | |
  b. Blinding of predictor assessment | D, V | ✓ | ✓ | |
 8. Sample size | ||||
  Arrival at study size | D,V | ✓ | ✓ | |
 9. Missing Data | ||||
  Handling of missing data | D, V | ✓ | ✓ | |
 10. Statistical analysis | ||||
  a. Handling of predictors in the analysis | D | ✓ | ✓ | |
  b. Specification of the model, all model building procedures, and internal validation methods | D | ✓ | ✓ | |
  c. For validation, description of how predictions were calculated | V | ✓ | n.a. | |
  d. Specification of all measures used to assess model performance | D, V | ✓ | ✓ | |
  e. Description of model updating | V | ✓ | ✓ | n.a. |
 11. Risk groups | ||||
  Details of how risk groups were created | D, V | ✓ | ✓ | ✓ |
 12. Development vs. validation | ||||
  For validation, description of differences between development and validation data | V | ✓ | ✓ | |
Results | ||||
 13. Participants | ||||
  a. Flow of participants through the study | D, V | ✓ | ✓ | |
  b. Description of characteristics of participants | D, V | ✓ | ✓ | |
  c. For validation, comparison with development data | V | ✓ | ✓ | |
 14. Model development | ||||
  a. Number of participants and outcome in each analysis | D | ✓ | ✓ | |
  b. Unadjusted association between each candidate predictor and outcome | D | ✓ | ✓ | ✓ |
 15. Model specification | ||||
  a. Presentation of full prediction model | D | ✓ | ✓ | ✓ |
  b. Explanation of how to use the prediction model | D | ✓ | ✓ | |
 16. Model performance | ||||
  Report of model performance measures | D,V | ✓ | ✓ | |
 17. Model updating | ||||
  Results from any model updating | V | ✓ | ✓ | n.a. |
Discussion | ||||
 18. Limitations | ||||
  Limitations | D, V | ✓ | ✓ | |
 19. Interpretation | ||||
  a. For validation, interpretation of performance measure results | V | ✓ | ||
  b. Overall interpretation of results | D, V | ✓ | ✓ | |
 20. Implications | ||||
  Potential clinical use of the model and implications for future research | D, V | ✓ | ✓ | |
Other information | ✓ | ✓ | ||
 21. Supplementary information | ||||
  Availability of supplementary resources | D, V | ✓ | ✓ | |
 22. Funding | ||||
  Source of funding and role of funders | D, V | ✓ | ✓ | |
Total number of applicable items for TRIPOD adherence score | 31 | 37 | ||